Study population
Plasma samples (n = 131) were selected from the Mass General Institute for Neurodegenerative Disease (MIND) biorepository, which includes plasma and CSF collected with research use consent at the time of diagnostic lumbar punctures at the Department of Neurology at Massachusetts General Hospital, and from the LifeSPAN biorepository, which contains plasma and CSF samples from healthy research participants. Clinical diagnoses were established by treating and research practitioners and confirmed in chart review by a senior neurologist (SEA) according to the 2011 National Institute of Aging-Alzheimer’s Association diagnostic criteria for AD12 and MCI due to AD13. Alzheimer’s disease (AD) biomarker status was verified with CSF biomarkers measured by the MIND Biomarker Core (Aß42/40 ratio, pTau181, and tTau immunoassays; Euroimmun, Lübeck, Germany) available in 117…
